iCARE

Interventional Radiology Reporting Standards and Checklist for Artificial Intelligence Research Evaluation (iCARE)

🔍 **Clinical Question:**  

How do we ensure the robustness of novel technological and artificial intelligence systems in Interventional Radiology specific contexts presented in peer-reviewed journals?

💡 **Key Insight:**  

This report introduces comprehensive standards and an evaluation checklist (iCARE) that covers the application of modern AI methods in IR-specific contexts.

👉 **Why it matters:**  

Comprehensive standards in reporting support the development of safe, generalizable technologies for enhancing IR workflows, the delivery of care, and patient outcomes.

➡️ **Full Article:**

brnw.ch... #InterventionalRadiology #AI #Checklist #MedEd

High-Dose Radioembolization Limited by Lung Shunt for HCC Supplied by IPA

High-Dose Radioembolization Limited by Lung Shunt for Hepatocellular Carcinoma Supplied by the Inferior Phrenic Artery

🔍 **Clinical Question:**  

Is radioembolization with lung-shunt limited high dose safe and effective via the inferior phrenic artery (IPA) supplying hepatocellular carcinoma (HCC)?

💡 **Key Insight:**  

Radioembolization via the inferior phrenic artery was performed with acceptable toxicity in 43 of 44 patients with single nodular or oligonodular hepatocellular carcinoma of 4–12 cm in diameter.

The complete response rate and objective response rate by 1 session of radioembolization were 44.2% and 97.7%, respectively. The 2-year and 5-year overall survival rates were 83.9% and 70.9%, respectively.

👉 **Why it matters:**  

Radioembolization with lung-shunt limited high dose can be performed with acceptable toxicity in patients with HCC supplied by the IPA.

➡️ **Full Article:**

brnw.ch... #InterventionalRadiology #IO #Y90 #HCC #MedEd

MRI-guided TULSA of Localized Prostate Cancer Thibault Tricard

Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial

🔍 **Clinical Question:**  

Is the TULSA-PRO device safe and effective in treating organ-confined low-risk to intermediate-risk prostate cancer (PCa)

💡 **Key Insight:**  

After 12 months, 43.5% of patients still had a biopsy-detectable cancerous tumor. However, there was a 40% recurrence-free rate and a 72% treatment-free survival rate at a median follow-up of 37 months.

Urinary and sexual dysfunction was common, with 26% developing stress incontinence, 35% developing overactive bladder, and 54% of potent patients developing erectile dysfunction.

👉 **Why it matters:**  

The TULSA-PRO device shows promising results for the focal treatment of localized prostate cancer, although it is not universally curative and was associated with urinary and sexual functional deficits.

➡️ **Full Article:** 

https://brnw.ch/21wVBIy

#InterventionalRadiology #IO #Ablation #ProstateCancer #MedEd